0.970
0.05 (5.42%)
| Previous Close | 0.920 |
| Open | 0.929 |
| Volume | 373,734 |
| Avg. Volume (3M) | 498,315 |
| Market Cap | 65,714,716 |
| Price / Sales | 840.89 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2026 |
| Operating Margin (TTM) | -41,252.01% |
| Diluted EPS (TTM) | -0.870 |
| Quarterly Revenue Growth (YOY) | 103.60% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | -47.70 M |
| Levered Free Cash Flow (TTM) | 34.37 M |
| Return on Assets (TTM) | -34.47% |
| Return on Equity (TTM) | -54.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | InflaRx N.V. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.44% |
| % Held by Institutions | 26.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dcf Advisers, Llc | 31 Dec 2025 | 158,500 |
| 52 Weeks Range | ||
| Median | 6.00 (518.56%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Dec 2025 | 6.00 (518.56%) | Buy | 1.02 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | InflaRx Announces Participation in February Investor Conferences |
| 08 Jan 2026 | Announcement | InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation |
| 30 Dec 2025 | Announcement | InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |